The Scientist: Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial

The Scientist | Oct. 1, 2021

Print

Tags »

Molnupiravir and Drug Development at Emory